Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
506.00    1.00 (0.20%)
Bid:
505.50
Ask:
506.50
Spread: 1.00 (0.198%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Board changes

29 Oct 2014 10:00

29 October 2014

Tate & Lyle PLC

Board changes

Tate & Lyle PLC (the “Company”) announces that Paul Forman has been appointed as a Non-Executive Director and a member of the Audit, Remuneration and Nominations Committees with effect from 1 January 2015.

Paul is Group Chief Executive of Coats plc, a leading industrial thread and consumer textile crafts business. Prior to joining Coats in 2009, he was Group Chief Executive of Low & Bonar PLC, a global performance materials group, and was previously Managing Director at Unipart International, a leading European automotive aftermarket supplier. Paul also served as a non-executive director at Brammer PLC from 2006 to 2010.

The Company further announces that Liz Airey, currently Chairman of the Audit Committee, will become Senior Independent Director and Anne Minto will assume the chairmanship of the Remuneration Committee with effect from 1 January 2015, after Robert Walker steps down from the Board following the completion of his term of appointment on 31 December 2014. Douglas Hurt will succeed Liz Airey as Chairman of the Audit Committee with effect from 1 March 2015 and will also replace her as a member of the Corporate Responsibility Committee from that date.

Sir Peter Gershon, Chairman of Tate & Lyle, said "I am delighted that Paul has agreed to join the Board. His wide experience of managing international businesses, developing business-to-business customer and market-led strategies, and commercialising innovation pipelines will be of significant benefit to the Board.

“I would also like to thank Robert for his nine years of exemplary service and significant contribution to the Board and the Remuneration Committee at a critical period in the Group’s transformation.”

There are no further disclosures to be made in connection with Mr Forman’s appointment pursuant to paragraph 9.6.13 of the Financial Conduct Authority’s Listing Rules.

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development group. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2014, Tate & Lyle sales totalled £3.1 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC.

Copyright Business Wire 2014

Date   Source Headline
4th Jun 20263:12 pmRNSForm 8.3 TATE & LYLE PLC
4th Jun 20262:45 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
4th Jun 20262:45 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
4th Jun 20262:25 pmRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle Plc
4th Jun 20262:23 pmRNSForm 8.3 - Tate & Lyle plc
4th Jun 20261:55 pmRNSForm 8.3 - Tate & Lyle plc
4th Jun 202612:57 pmRNSForm 8.3 - Tate & Lyle plc
4th Jun 202611:53 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
4th Jun 202611:32 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
4th Jun 202611:22 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
4th Jun 202611:19 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
4th Jun 202611:16 amRNS20260603_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
4th Jun 202611:14 amRNS20260603_TATE & LYLE_8.5 EPT RI_UK_MLI
4th Jun 202610:59 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
4th Jun 202610:40 amRNSForm 8.3 - Tate & Lyle PLC
4th Jun 20269:25 amRNSForm 8.5 (EPT/RI)
3rd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20263:16 pmRNSForm 8.3 TATE & LYLE PLC
3rd Jun 20262:25 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
3rd Jun 20261:56 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
3rd Jun 20261:56 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20261:40 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 202611:57 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
3rd Jun 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:11 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
3rd Jun 202611:02 amRNS20260602_TATE & LYLE_8.5 EPT RI_UK_MLI
3rd Jun 202610:41 amRNSForm 8.3 - Tate & Lyle PLC
3rd Jun 202610:24 amRNSForm 8.5 (EPT/RI)
2nd Jun 20265:13 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
2nd Jun 20265:00 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
2nd Jun 20264:33 pmRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
2nd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
2nd Jun 20263:00 pmRNSForm 8.3 TATE & LYLE PLC
2nd Jun 20262:47 pmRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20262:30 pmRNSAnnual Financial Report and Notice of Meeting 2026
2nd Jun 202612:33 pmRNSForm 8.3 - Tate & Lyle PLC
2nd Jun 202611:47 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:45 amRNS20260601_TATE & LYLE_8.5 EPT RI_UK_MLI
2nd Jun 202611:44 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:32 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
2nd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20268:42 amRNSForm 8.5 (EPT/RI)
1st Jun 20265:27 pmRNS20260526_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:22 pmRNS20260526_TATELYLE8.5 EPT NON-RI BOFASE_replacement
1st Jun 20265:17 pmRNS20260522_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:10 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
1st Jun 20264:55 pmRNS20260521_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20263:35 pmRNSDirector/PDMR Shareholding
1st Jun 20263:30 pmRNSForm 8.3 - Tate & Lyle plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.